Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
RYSE Asset Management is a venture capital firm founded in 2017 and headquartered in London, United Kingdom. The firm focuses on driving innovation in healthcare through HealthTech solutions, aiming to improve access, quality, and delivery of healthcare services, particularly in underserved areas. RYSE has established itself as a key player in the HealthTech investment space, with a portfolio that includes nine companies.
As of now, RYSE manages a significant amount of assets under management (AUM) and has launched the Special Opportunities HealthTech Fund in January 2024, which aims to invest in innovative HealthTech solutions that enhance healthcare access and quality. The firm is well-positioned within the UK healthcare sector, providing its portfolio companies with access to leading NHS initiatives and a network of clinical and technology talent.
RYSE specializes in investing in early-stage HealthTech companies, primarily at the Seed and Series A stages. The firm targets sectors such as digital diagnostics, digital therapeutics, medical devices, and data and discovery platforms. Their investment strategy emphasizes addressing unmet clinical needs and improving access to affordable healthcare solutions. RYSE seeks to partner with founders who are committed to making a meaningful impact in healthcare.
The firm looks for startups that demonstrate innovative approaches to solving healthcare challenges, particularly those that can improve patient outcomes and enhance the efficiency of healthcare delivery. RYSE's investment thesis is centered on the belief that addressing gaps in healthcare access and quality can lead to significant advancements in the industry.
RYSE's portfolio includes nine notable companies that are making strides in the HealthTech sector:
These companies reflect RYSE's commitment to investing in innovative solutions that address critical healthcare needs and improve patient outcomes.
Dr. John Lee Allen - CEO: Dr. Allen has extensive experience in the healthcare sector, focusing on HealthTech innovations. He has previously held leadership roles in various healthcare organizations and has a strong background in clinical research.
Kevin Roberts - CEO in Residence: Kevin brings a wealth of experience in venture capital and startup growth. He has successfully led multiple HealthTech investments and is known for his expertise in scaling early-stage companies.
To pitch to RYSE, founders should send their proposals via email to investments@ryseam.com. It is essential to include a comprehensive pitch deck that outlines the business model, market opportunity, and how the solution addresses specific healthcare challenges. RYSE values clarity and detail in the pitch materials.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review of the pitch.
In January 2024, RYSE launched the Special Opportunities HealthTech Fund, aimed at investing in innovative HealthTech solutions that improve healthcare access and quality. This fund reflects RYSE's ongoing commitment to supporting early-stage companies in the HealthTech sector.
RYSE has been actively involved in supporting its portfolio companies, with founders providing testimonials about the strategic support and access to healthcare networks that RYSE offers. This involvement has been crucial for startups looking to navigate the complexities of the healthcare market.
What are RYSE's investment criteria?
RYSE invests in early-stage HealthTech companies at the Seed and Series A stages, focusing on sectors such as digital diagnostics, digital therapeutics, medical devices, and data and discovery platforms. The firm emphasizes addressing unmet clinical needs and improving healthcare access and affordability.
How can I apply or pitch to RYSE?
Founders can pitch their ideas to RYSE by sending an email to investments@ryseam.com. It is advisable to include a detailed pitch deck that outlines the business model, market opportunity, and how the solution addresses specific healthcare challenges.
What makes RYSE different from other venture capital firms?
RYSE distinguishes itself through its strong focus on HealthTech innovation and its established network within the UK healthcare sector. The firm provides portfolio companies with access to leading NHS initiatives and strategic support to enhance their growth potential.
What is RYSE's geographic scope?
RYSE primarily invests in companies based in Europe, with a particular emphasis on the United Kingdom. The firm is dedicated to supporting HealthTech solutions that can improve healthcare delivery in these regions.
What is RYSE's post-investment involvement like?
RYSE actively supports its portfolio companies by providing access to healthcare networks, strategic guidance, and resources to help them scale effectively. Founders have reported positive experiences regarding the firm's involvement in their growth journeys.
What is the typical check size for RYSE's investments?
RYSE typically invests at the Seed and Series A stages, with check sizes varying based on the specific needs of the startup and the potential for impact in the healthcare sector.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.